Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy

Table 2

Clinical characteristics of recurrent VH and treatments.

Patients	Number of rebleeding episodes	Number of IVIR for RVH	No. of S.PRP	TRT of RVH (weeks)	Surgical intervention (V/AVI)
1	2	3	1	13	No
2	1	2	1	8	No
3	1	2	1	7	No
4	2	5	2	15	No
5	1	1	0	5	No
6	1	2	1	7	No
7	2	5	/	29	V
8	3	6	/	38	V
9	1	1	0	2	No
10	2	4	/	21	V/V
11	1	1	1	3	No
12	2	6	/	29	V
13	2	4	1	15	No
14	1	5	/	11	V
15	3	5	/	17	V
16	3	6	1	21	No
17	1	4	/	36	V/V/AVI
18	2	5	/	44	V/V + AVI

No. of S.PRP = number of supplementary PRP in patients without surgical intervention; IVIR = intravitreal injection of ranibizumab; RVH = recurrent vitreous hemorrhage; TRT = total reabsorption time; V = vitrectomy; AVI = Ahmed valve implantation; V/V = two vitrectomies at different time; represents patients having surgical intervention.